Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2176 to 2190 of 7707 results

  1. Stockholm3 blood test for prostate cancer, (MT734),

      Status ...

    Diagnostics guidance
    Topic selection

  2. PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes, (MT740)

      Status ...

    Diagnostics guidance
    Topic selection

  3. Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy, (MT158)

      Status ...

    Diagnostics guidance
    Topic selection

  4. Jada, (MT826)

      Status ...

    Medical technologies guidance
    Topic selection

  5. Urolon, (MT821)

      Status ...

    Medical technologies guidance
    Topic selection

  6. BPMpathway for rehabilitation support in joint replacement surgery, (MIB319)

      Status ...

    Medical technologies guidance
    Topic selection

  7. LIVERFASt for diagnosing and staging liver injury and chronic liver disease, (MT783)

      Status ...

    Diagnostics guidance
    Topic selection

  8. iQoro neuromuscular training device, (MT809)

      Status ...

    Medical technologies guidance
    Topic selection

  9. Spectra Optia for plasma exchange, (MT828)

      Status ...

    Medical technologies guidance
    Topic selection

  10. Electrosurgery (diathermy and coblation) for tonsillectomy, (IP324/2)

      Status ...

    Medical technologies guidance
    Topic selection

  11. Subcutaneous amivantamab for treating advanced non-small-cell lung cancer with EGFR mutations TSID 12011

      Status ...

    Technology appraisal guidance
    Topic selection

  12. Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer TSID 12021

    Awaiting development [GID-TA11556] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer TSID 12044

    Awaiting development [GID-TA11558] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]

    Awaiting development [GID-TA11025] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]

    Awaiting development [GID-TA11092] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development